Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study

Isabella Iacona, Mario Lazzarino, Maria Antonietta Avanzini, Maurizio Rupolo, Luca Arcaini, Cesare Astori, Francesca Lunghi, Ester Orlandi, Enrica Morra, Vittorina Zagonel, Mario B. Regazzi

Research output: Contribution to journalArticlepeer-review

Abstract

Rituximab is a chimeric monoclonal antibody (MAb) directed against the B-cell CD20 antigen that has been approved for therapy of relapsed and resistant follicular non-Hodgkin's lymphoma (NHL). This study describes the development and validation of a highly sensitive, rapid, accurate, precise enzyme-linked immunosorbent assay (ELISA) to measure Rituximab serum concentrations. This study also describes the application of the ELISA method to a pharmacokinetic study in a homogeneous group of patients with follicular lymphoma who received 4 weekly doses of MAb at the standard dose of 375 mg/m2 as consolidation of chemotherapy. In the patients in this study, the median Rituximab serum concentrations increased during therapy, and showed a slow decline during the posttreatment period. The Rituximab elimination half- life of approximately 20 days accounts for the demonstrated accumulation of MAb in serum samples. Because previous pharmacokinetic studies showed a correlation between Rituximab serum levels and tumor response, the ELISA method used in this study, which allows a precise control of serum concentrations, could be useful for predicting the final response to the MAb and for selecting patients able to benefit from higher dosage or repeated drug administration.

Original languageEnglish
Pages (from-to)295-301
Number of pages7
JournalTherapeutic Drug Monitoring
Volume22
Issue number3
DOIs
Publication statusPublished - Jun 2000

Keywords

  • CD20 antigen
  • ELISA
  • Follicular NHL
  • Pharmacokinetics
  • Rituximab

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study'. Together they form a unique fingerprint.

Cite this